Overview
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
Eligibility
Inclusion Criteria:
- Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;
- Positive PD-L1 expression;
- ECOG score ≤1
Exclusion Criteria:
- Positive parametrium or surgical margin;
- Incomplete radical surgery;
- Residual target lesions;
- Active autoimmune disease or autoimmune disease requiring systemic treatment;
- Previous treatment with immune checkpoint inhibitors.